Garenoxacin

Research use only, not for human use.

A quinolone antibiotic for the treatment of Gram-positive and Gram-negative bacterial infections.

A quinolone antibiotic for the treatment of Gram-positive and Gram-negative bacterial infections.Bacterial Infection Approved.

Garenoxacin (BMS284756) (0-8 days) inhibits mycoplasmas and ureaplasmas with MIC90s ≤0.25 μg/mL against tested strains.Garenoxacin (48 h) inhibits S. aureus wild type and mutants with MICs of 0.0128-4.0 μg/mL. Garenoxacin inhibits topoisomerase IV and gyrase from S. aureus with IC50s of 1.25 to 2.5 and 1.25 μg/mL, respectively.Garenoxacin has a low propensity for selective enrichment of fluoroquinolone-resistant mutants among ciprofloxacin-susceptible isolates of S. aureus. :Cell Viability Assay Cell Line:M. pneumonia, M. fermentans, M. hominis and Ureaplasma spp.Concentration:Incubation Time:24 h for Ureaplasma spp., 48 h for M. hominis, 4 to 8 days for M. pneumonia Result:Showed inhibition with MIC90s of 0.031 μg/mL, ≤0.008 μg/mL, ≤0.008 μg/mL and 0.25 μg/mL against M. pneumonia, M. fermentans, M. hominis and Ureaplasma spp. strains, respectively.

Garenoxacin (12.5-50 mg/kg; s.c.; once) is highly effective against the wild-type strain and mutants harboring a single mutation in a mouse pneumonia model with S. pneumonia infection.Garenoxacin (10 and 30 mg/kg; p.o.; once) reduces the viable cell counts in the lungs and significantly prolongs survival on experimental secondary pneumococcal pneumonia caused by S. pneumoniae D-979 in BALB/c female mice. Animal Model:Swiss mice with S. pneumonia infection.Dosage:12.5, 25 and 50 mg/kg Administration:Subcutaneous injection, once Result:Significantly improved the survival rate.

BMS284756 | BMS 284756 | BMS-284756 | Garenoxacin. tradename Geninax

GPCR/G Protein

Antibacterial

Antibacterial

Infection

Bacterial Infection

194804-75-6

426.4127

C23H20F2N2O4

>98% (HPLC)

10 mM in DMSO

O=C(C1=CN(C2CC2)C3=C(C=CC(C4=CC5=C([C@@H](C)NC5)C=C4)=C3OC(F)F)C1=O)O

3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-2,3-dihydro-1-methyl-1H-isoindol-5-yl]-1,4-dihydro-4-oxo-

(-20℃)

With Ice Pack

≥ 2 years